Which has better valuation and earnings, RZLT or CRDL?

Rezolute is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A

Is RZLT or CRDL more profitable?

Rezolute's return on equity of -58.82% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Cardiol Therapeutics N/A -229.43% -165.60%

Is EVMN or CRDL more profitable?

Evommune's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Cardiol Therapeutics N/A -229.43% -165.60%

Does the media favor EVMN or CRDL?

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Evommune. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 6 mentions for Evommune. Evommune's average media sentiment score of 1.53 beat Cardiol Therapeutics' score of 0.62 indicating that Evommune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cardiol Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EOLS or CRDL more profitable?

Cardiol Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% Cardiol Therapeutics N/A -229.43% -165.60%

Does the media prefer EOLS or CRDL?

In the previous week, Cardiol Therapeutics had 4 more articles in the media than Evolus. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 3 mentions for Evolus. Cardiol Therapeutics' average media sentiment score of 0.62 beat Evolus' score of 0.38 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CRDL or BNTC?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A

Is CRDL or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Benitec Biopharma N/A -34.82% -34.11%

Does the media prefer CRDL or BNTC?

In the previous week, Cardiol Therapeutics had 5 more articles in the media than Benitec Biopharma. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.93 beat Cardiol Therapeutics' score of 0.62 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiol Therapeutics (CRDL) Competitors

$1.11 -0.04 (-3.48%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+0.90%)

As of 06:34 AM Eastern

Compare

CRDL vs. CCCC, RZLT, EVMN, EOLS, and BNTC

Should you buy Cardiol Therapeutics stock or one of its competitors? MarketBeat compares Cardiol Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiol Therapeutics include C4 Therapeutics (CCCC), Rezolute (RZLT), Evommune (EVMN), Evolus (EOLS), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry.

How does Cardiol Therapeutics compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

C4 Therapeutics currently has a consensus target price of $7.75, suggesting a potential upside of 103.95%. Cardiol Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 665.77%. Given Cardiol Therapeutics' higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cardiol Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$34.86M	12.05	-$104.99M	-$1.19	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

C4 Therapeutics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

In the previous week, Cardiol Therapeutics had 6 more articles in the media than C4 Therapeutics. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Cardiol Therapeutics' score of 0.62 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
C4 Therapeutics	Very Positive
Cardiol Therapeutics	Positive

Summary

C4 Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Rezolute is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Rezolute's return on equity of -58.82% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Rezolute has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, Cardiol Therapeutics had 6 more articles in the media than Rezolute. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 1 mentions for Rezolute. Rezolute's average media sentiment score of 1.89 beat Cardiol Therapeutics' score of 0.62 indicating that Rezolute is being referred to more favorably in the media.

Company	Overall Sentiment
Rezolute	Very Positive
Cardiol Therapeutics	Positive

Rezolute presently has a consensus price target of $9.38, indicating a potential upside of 97.78%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 665.77%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

83.0% of Rezolute shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Rezolute beats Cardiol Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Evommune?

Evommune (NYSE:EVMN) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Evommune's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.43%	-165.60%

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Evommune. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 6 mentions for Evommune. Evommune's average media sentiment score of 1.53 beat Cardiol Therapeutics' score of 0.62 indicating that Evommune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cardiol Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has lower revenue, but higher earnings than Evommune. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	34.52	-$68.87M	-$9.50	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Evommune currently has a consensus target price of $45.63, indicating a potential upside of 266.23%. Cardiol Therapeutics has a consensus target price of $8.50, indicating a potential upside of 665.77%. Given Cardiol Therapeutics' higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Evommune beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Evolus?

Evolus (NASDAQ:EOLS) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Evolus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

In the previous week, Cardiol Therapeutics had 4 more articles in the media than Evolus. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 3 mentions for Evolus. Cardiol Therapeutics' average media sentiment score of 0.62 beat Evolus' score of 0.38 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.32	-$51.64M	-$0.67	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Evolus presently has a consensus price target of $16.00, indicating a potential upside of 168.46%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 665.77%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

90.7% of Evolus shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cardiol Therapeutics beats Evolus on 8 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Benitec Biopharma?

Cardiol Therapeutics (NASDAQ:CRDL) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cardiol Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 665.77%. Benitec Biopharma has a consensus target price of $27.00, indicating a potential upside of 107.37%. Given Cardiol Therapeutics' higher probable upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Benitec Biopharma's return on equity of -34.82% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Benitec Biopharma	N/A	-34.82%	-34.11%

In the previous week, Cardiol Therapeutics had 5 more articles in the media than Benitec Biopharma. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.93 beat Cardiol Therapeutics' score of 0.62 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Benitec Biopharma is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Summary

Cardiol Therapeutics beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$132.53M	$3.01B	$6.77B	$12.55B
Dividend Yield	N/A	2.08%	2.68%	9.45%
P/E Ratio	-3.96	19.41	27.07	24.35
Price / Sales	N/A	371.56	492.98	75.42
Price / Cash	N/A	56.68	48.63	60.00
Price / Book	10.09	4.26	10.82	6.31
Net Income	-$24.20M	$65.13M	$3.59B	$331.55M
7 Day Performance	11.90%	-2.62%	-1.78%	-0.71%
1 Month Performance	4.72%	3.29%	3.70%	0.16%
1 Year Performance	-14.62%	20.83%	27.38%	19.66%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	1.9572 of 5 stars	$1.11 -3.5%	$8.50 +665.8%	-14.0%	$132.53M	N/A	N/A	20	Analyst Forecast
CCCC C4 Therapeutics	1.8516 of 5 stars	$4.14 -3.7%	$7.75 +87.2%	+80.1%	$475.44M	$35.95M	N/A	150
RZLT Rezolute	3.2242 of 5 stars	$4.93 +0.4%	$9.38 +90.2%	-7.2%	$472.80M	N/A	N/A	40
EVMN Evommune	3.6291 of 5 stars	$12.31 -5.0%	$45.63 +270.6%	N/A	$466.80M	$13M	N/A	45	Positive News
EOLS Evolus	2.0334 of 5 stars	$6.99 +1.3%	$16.00 +128.9%	-35.7%	$454.40M	$297.18M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. CCCC, RZLT, EVMN, EOLS, and BNTC

How does Cardiol Therapeutics compare to C4 Therapeutics?

Summary

How does Cardiol Therapeutics compare to Rezolute?

Summary

How does Cardiol Therapeutics compare to Evommune?

Summary

How does Cardiol Therapeutics compare to Evolus?

Summary

How does Cardiol Therapeutics compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. CCCC, RZLT, EVMN, EOLS, and BNTC

How does Cardiol Therapeutics compare to C4 Therapeutics?

Do institutionals & insiders believe in CCCC or CRDL?

Do analysts prefer CCCC or CRDL?

Which has stronger earnings and valuation, CCCC or CRDL?

Which has more volatility & risk, CCCC or CRDL?

Is CCCC or CRDL more profitable?

Does the media refer more to CCCC or CRDL?

Summary

How does Cardiol Therapeutics compare to Rezolute?

Which has better valuation and earnings, RZLT or CRDL?

Is RZLT or CRDL more profitable?

Which has more risk and volatility, RZLT or CRDL?

Does the media refer more to RZLT or CRDL?

Do analysts prefer RZLT or CRDL?

Do insiders & institutionals believe in RZLT or CRDL?

Summary

How does Cardiol Therapeutics compare to Evommune?

Is EVMN or CRDL more profitable?

Does the media favor EVMN or CRDL?

Which has higher earnings & valuation, EVMN or CRDL?

Do insiders and institutionals believe in EVMN or CRDL?

Do analysts prefer EVMN or CRDL?

Summary

How does Cardiol Therapeutics compare to Evolus?

Which has more volatility & risk, EOLS or CRDL?

Is EOLS or CRDL more profitable?

Does the media prefer EOLS or CRDL?

Which has preferable valuation & earnings, EOLS or CRDL?

Do analysts prefer EOLS or CRDL?

Do institutionals & insiders believe in EOLS or CRDL?

Summary

How does Cardiol Therapeutics compare to Benitec Biopharma?

Do institutionals and insiders believe in CRDL or BNTC?

Do analysts prefer CRDL or BNTC?

Is CRDL or BNTC more profitable?

Does the media prefer CRDL or BNTC?

Which has more risk and volatility, CRDL or BNTC?

Which has stronger earnings and valuation, CRDL or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools